Preoperative chemoradiotherapy currently serves as the standard treatment for locally advanced (T3, T4 with or without positive nodes) rectal cancer. Patients treated with chemoradiotherapy had lower rates of local recurrence and toxicity and similar rates of survival compared with patients receiving postoperative chemoradiotherapy. In rectal cancer treatment, the most frequently used drug in combination with radiotherapy (RT) is 5-fluorouracil (5-FU)/leucovorin (LV). The most common preoperative chemoradiotherapy regimes include 45-50.4 Gy of pelvic RT in addition to concurrent 5-FU in the first and last weeks of RT or prolonged continuous infusion of 5-FU for the whole RT course.

In the Intergroup 0144 trial, no significant differences were observed in the overall survival (OS) and relapse-free survival (RFS) among different regimens of 5-FU–based postoperative therapy. On the other hand, in the Gastrointestinal Intergroup trial, patients treated with postoperative RT with concurrent protracted venous infusion of 5-FU had significantly higher rates of OS and RFS compared with those given bolus 5-FU.

Continuous infusion has the biological advantage of prolonging the exposure of cells to 5-FU, thus improving antitumor activity, while its disadvantages include the need for indwelling central venous catheter and infusion pumps, with potential risks of complications such as infection, bleeding, venous thrombosis, and increased cost of treatment. For this reason, we use bolus 5-FU routinely.
in our department for chemoradiotherapy of locally advanced rectal cancer. Furthermore, not all the patients can cooperate to take 5-day 5-FU treatment. In such cases, other fluoropyrimidines [capecitabine (CA), tegafur-uracil (UFT)] or thymidylate synthase inhibitors (raltitrexed) are applied.

CA is an orally administered fluoropyrimidine carbamate which is preferentially converted to active 5-FU through a three-step enzymatic pathway in the liver and in the tumor cells. When administered on a twice-daily schedule, it may mimic the pharmacokinetics of a protracted 5-FU infusion. CA has been shown in two randomized trials to be at least equivalent in efficacy to bolus 5-FU/LV in the treatment of metastatic colorectal cancers. It was associated with a higher rate of tumor response and lesser toxicity but equivalent survival when compared with bolus 5-FU/LV. Several phase II trials have used CA and preoperative RT for locally advanced rectal cancers and have shown that this combined treatment was well tolerated by patients and the rate of pathologic response was comparable to that of preoperative 5-FU/LV and RT. Also, a recent randomized phase III trial in Germany confirmed that OS rates did not change when infused 5-FU/LV was replaced by CA during RT and adjuvant chemotherapy.

CA cannot be used routinely in our country instead of 5-FU to decrease the probable toxicity of 5-FU. Barely CA is chosen, mainly depending on patient’s economic status, since CA is not covered by the medical insurance system in our country. Generally, 5-FU is the only agent which is used.

This study was undertaken to compare the outcome of preoperative CA plus RT versus intermittent 5-FU/LV modulation plus RT in locally advanced rectal cancers. The goal of this study is to analyze the toxicity, pathologic response, relapse rate, and survival differences in locally advanced rectal cancer patients treated with either preoperative RT with concurrent 5-FU/LV or preoperative RT with concurrent CA.

MATERIALS AND METHODS

Patient selection
Sixty patients with histologically confirmed rectal adenocarcinoma and no evidence of distant metastasis or no previous history of pelvic RT, who were treated with preoperative RT with concurrent 5-FU/LV and concurrent CA followed by surgery between January 2008 and December 2011 were included.

Acute toxicity was graded using the Radiation Therapy Oncology Group (RTOG) Acute Radiation Morbidity Scoring Criteria.

Staging evaluation
Pretreatment evaluation included a complete history taking and physical examination assessed at baseline by chest X-ray, abdominal and pelvic computed tomography (CT) plus flexible endoscopy. Endoscopic ultrasonography (EUS) was performed for some patients. Clinical stage was determined based on the CT and EUS findings. The American Joint Committee on Cancer TNM 2002 system was used for staging. The clinical stage was T3 for 18 (72%) and T4 for 7 (28%) patients in the 5-FU/LV group and T3 for 28 (80%) and T4 for 7 (20%) patients in the CA group. The clinical stage was N0 for 20 (80%) and N+ for 5 (20%) patients in the 5-FU/LV group and N0 for 28 (80%) and N+ for 7 (20%) patients in the CA group.

Treatment
RT began on the first day of chemotherapy and was administered five times per week with a daily fraction of 180 cGy. Initially, the entire pelvis was treated with 3- or 4-field techniques to 4500 cGy in a supine position. The superior border of the entire pelvis was placed at the lumbosacral junction. The inferior border was placed at 2 cm caudal to the gross tumor. The lateral field border was 1.5 cm outside the bony pelvic inlet. The anterior border of the lateral fields was 3 cm anterior to the gross tumor and shaped to include the internal iliac lymph nodes if T3 and the external iliac lymph nodes if T4. The posterior border of the lateral fields was extended to encompass the bony sacrum. Most patients received a boost to the primary tumor bed for a median total dose of 5040 cGy. A two-dimensional conventional technique or three-dimensional conformal technique was used according to the attending physician’s choice.

Either 5-FU (425 mg/m²) or LV (25 mg/m²) was administered during the first 4 days in the first week and then restarted for 3 days in the fifth week of the treatment course, or CA was administered concomitantly with RT at a dose of 825 mg/m² twice daily (bid) during the whole period of RT (days 1-33) without giving weekend breaks. CA doses were given every 12 hours with one of the doses administered 2 hours prior to irradiation. If RT was interrupted, chemotherapy was not administered.

Definitive surgery was scheduled 6 weeks after the completion of the chemoradiotherapy. The choice of surgical procedure was either low anterior resection (LAR) (50%) or abdominoperineal resection (APR) (50%).
In addition to concurrent chemotherapy, four courses of chemotherapy were planned postoperatively. This comprised either CA 1250 mg/m\(^2\) bid on days 1-14 every 3 weeks for 4 cycles or bolus i.v. 5-FU 425 mg/m\(^2\)/day and LV 20 mg/m\(^2\)/day on days 1-5 of each cycle repeated every 4 weeks.

**Ethical consideration**
Following the legal and penal codes in the country, it is mandatory to have a signature-bearing certificate of each patient stating their personal approval to be enrolled in such study.

**Statistical analysis**
The patient characteristics, toxicities, downstaging, and sphincter preservation were compared among the two groups using Chi-square test, Fisher’s exact test or Student’s t-test, and Kruskal-Wallis test, for which \(P\) values less than 0.05 were considered to be statistically significant.

Kaplan-Meier method was used to estimate disease-free survival (DFS) and OS. Survival differences between the two groups were tested by log-rank test. Hazard ratios, 95% confidence intervals (CI), and \(P\) values were calculated. All statistical analyses were conducted using the SPSS (version 10.0) statistical software program. Cox regression analysis was used to determine the effective factors in DFS and OS.

**RESULTS**

**Patient characteristics**
The patient characteristics are shown in Table 1. Their median age was 55 (range 36-80) years.

**Acute toxicity**
The highest grades of acute toxicity during chemoradiotherapy in each group are shown in Table 2. Patients treated with 5-FU/LV had a higher rate of grade 2 gastrointestinal toxicity compared to CA group patients (diarrhea, rectal pain/tenesmus, and mucositis) (65.2% and 34.3%, respectively, \(P = 0.008\)), whereas CA group had a higher rate of grade 1 dermatologic toxicity in comparison to 5-FU/LV group (20% and 4%, respectively, \(P = 0.030\)). Also, 5-FU/LV group had a higher rate of grade 1 hematologic toxicity (\(P = 0.030\)).

None of the patients required hospitalization or dose reduction, discontinuation, or other modification during chemoradiotherapy and chemotherapy.

**Surgery and pathologic response**
No statistically significant difference was found in the rate of pathologic complete response [Table 3]. Tumor downstaging was determined by comparing pretreatment T stage (as defined by clinical, radiographic, and ultrasound staging)
and the pathologic stage. The post-chemoradiation N-stage was not changed in the two groups. Although tumor downstaging was observed in each group, significant difference was found in the rate of downstaging in patients treated with 5-FU/LV (60%) compared with patients treated with CA (37.1%) (P = 0.026).

Surgery of 12 (48%) of patients treated with 5-FU/LV consisted of sphincter-sparing surgery methods including LAR, and that of 13 patients consisted of APR (52%). Of the patients treated with CA, 18 (51.4%) underwent sphincter-sparing surgery including LAR. The other patients (n = 17) were treated with APR (48.6%). There was no statistically significant difference in sphincter preservation rates between the two groups (P = 0.912). There were no statistically significant differences between the groups in positive surgical margin rates after surgery (P = 0.585).

In addition to acute toxicity of chemoradiotherapy, postoperative complications such as anastomotic leakage were not observed.

**Relapses and survivals**

During a median follow-up period of 38 months (range 3-61), 10 patients (16.7%) had local recurrences and 11 patients (18.3%) had developed distant recurrences. Local recurrences were seen in five patients (20%) the 5-FU/LV group and in five patients (14.3%) in the CA group. There was no statistically significant difference between groups with respect to local recurrence rates (P = 0.510).

Distant metastasis was seen in five patients (20%) who had been treated with 5-FU/LV and in six (17.1%) patients who had been treated with CA. Similar to metastasis rates, no statistically significant difference was found in metastasis frequency rates (P = 0.721).

The OS rates for all patients were 80.2% and 70% after 3 and 5 years, respectively, and for the DFS, the rates were 75.7% and 67.1% after 3 and 5 years, respectively.

The 3-5 year DFS rates in the 5-FU/LV group were 76.3% and 59.4%, respectively, while in the CA group, the rates were 75.1% and 74.8%, respectively (P = 0.08). The 3-5 year OS rates in cases treated with 5-FU/LV were 81.1% and 64.4%, respectively, and were 79.2% and 75.1%, respectively, in cases treated with CA (P = 0.09). There was no statistically significant difference between the DFS and OS rates in both groups.

All prognostic factors listed below for DFS and OS rates have been evaluated by univariate analysis and no statistically significant differences were found regarding age, gender, pretreatment hemoglobin level, toxicity, post-treatment TNM, histologic subgroups, grade, surgical experience, time interval between RT and surgery, operation type, chemotherapy agent, and localization of tumor.

**DISCUSSION**

5-FU is currently accepted as the standard cytotoxic agent for preoperative chemoradiotherapy of rectal cancer. Considering the disadvantages of continuous infusion, there are studies evaluating alternative agents. These are mainly oral agents. Although these studies demonstrated no significant difference compared to 5-FU applied either continuously or as bolus, toxicity differences were reported. Kim et al.[17] retrospectively reported that preoperative chemoradiation with oral CA is more tolerable with respect to side effects, and offers a more effective treatment modality than bolus 5-FU/LV, as measured by tumor downstaging, pathologic response, and sphincter preservation.

On the other hand, another retrospective trial demonstrated significant difference only in downstaging when CA was compared to continuous infusion (CI) 5-FU.[18,19] Another retrospective trial comparing CA with CI 5-FU showed no significant difference among these two agents in means of toxicity or survival. Also, neoadjuvant radiochemotherapy with CA should be considered an effective treatment option to avoid local recurrence and also to improve survival in elderly rectal cancer patients.[20]

A recent randomized phase III trial in Germany confirmed that the endpoint OS rates did not change when infused 5-FU was replaced by CA during RT and adjuvant chemotherapy.[16] Likewise, in another study of Kim et al.,[21] no difference was found either in radiologic or pathologic outcomes between 5-FU and CA in post-therapeutic early stage.

Despite the similarity between the results with 5-FU and CA, since the toxicity is found to be more tolerable with CA, recently the researches combining CA with irinotecan and oxaliplatin are favored.[22,23]

Early results from the National Surgical Adjuvant Breast and Bowel Project (NSABP) R-04[24] and Lee et al.[25] trials did not confirm a significant improvement of short-term endpoints such as the pathologic complete response rate by addition of oxaliplatin or irinotecan. But results of several preoperative chemoradiotherapy phase I/II studies using CA/irinotecan or oxaliplatin at various dosages and schedules have shown encouraging tumor response rates and toxicity profiles.

In this study, distribution of these two groups is not balanced for the following reasons. While well-differentiated cases in CA arm are high, poorly differentiated cases are dominant in 5-FU/LV arm. There are differences in RT applications,
as two-field technique was used in FU arm and three- or four-field conformal RT was used in CA arm. Despite its disadvantages downstaging is significantly better with FL arm.

The main toxicities of bolus 5-FU injection are oral mucositis, gastrointestinal toxicity (diarrhea), myelosuppression, and skin toxicity. In a randomized phase III trial, CA was less toxic than bolus 5-FU/LV when administered to patients with advanced colorectal cancer.[11] Oral CA treatment results in a significantly lower rate of myelosuppression, diarrhea, stomatitis, nausea, and alopecia than bolus 5-FU/LV treatment. Grade 3 hand-foot syndrome developed more frequently after oral CA treatment than after bolus 5-FU/LV treatment. In patients receiving high-dose CI 5-FU/LV, hand-foot syndrome was a frequent side effect, but it did not significantly affect patients’ quality of life or the delivery of the planned chemotherapy.[24] In this study, grade 2 leukopenia and thrombocytopenia occurred only in the bolus 5-FU/LV group, with no incidences of these toxicities in the oral CA group. The most commonly occurring grade 3 non-hematologic toxicities were diarrhea and grade 1 leukopenia and thrombocytopenia in the bolus 5-FU/LV treatment group, and hand-foot syndrome in the oral CA group. Statistically, there was less diarrhea and radiation dermatitis in the latter group.

The present study, examining short-term tumor responses, pathologic response rates, surgical margin status, local control rates, DFS, and OS, could not demonstrate any significant differences between CA and bolus injection of 5-FU/LV for preoperative chemoradiation of locally advanced rectal cancer. Long-term results and prospective randomized trials are needed.

REFERENCES

1. Das P, Lin EH, Bhatia S, Skipper JM, Rodriguez-Bigas MA, Feig BW, et al. Preoperative chemoradiation with capecitabine versus protracted infusion 5-fluorouracil for rectal cancer: A matched-pair analysis. Int J Radiat Oncol Biol Phys 2006;66:1378-83.

2. Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, et al. German Rectal Cancer Study Group. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351:1731-40.

3. Krook JE, Moertel CG, Gunderson LL, Wieand HS, Collins RT, Beart RW, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 1991;324:709-15.

4. O’Connell MJ, Martenson JA, Wieand HS, Krook JE, Macdonald JS, Haller DG, et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 1994;331:502-7.

5. Smalley SR, Benedetti JK, Williamson SK, Robertson JM, Estes NC, Maher T, et al. Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144. J Clin Oncol 2006;24:3542-7.

6. Martenson JA, Shanahan TG, O’Connell MJ, Coban CD, Schroeder G, Burch PA, et al. Phase I study of 5-fluorouracil administered by protracted venous infusion, leucovorin and pelvic radiation therapy. Cancer 1999;86:710-4.

7. Gambacorta MA, Valentini V, Morganti AG, Mantini G, Micciche F, Ratto C, et al. Chemoradiation with raltitrexed (Tomudex) in preoperative treatment of stage II-III resectable rectal cancer: A phase II study. Int J Radiat Oncol Biol Phys 2004;60:130-8.

8. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998;34:1274-81.

9. Schüller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 2000;45:291-7.

10. Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, et al. Xeloda Colorectal Cancer Study Group. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study. J Clin Oncol 2001;19:4097-106.

11. Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study. J Clin Oncol 2001;19:2292-92.

12. Dunst J, Reese T, Sutter T, Zühlke H, Hinke A, Kölling-Schlebusch K, et al. Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer. J Clin Oncol 2002;20:3983-91.

13. Kim JS, Cho MJ, Song KS, Yoon WH. Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2002;54:403-8.

14. Krishnan S, Janjan NA, Skibber JM, Rodriguez-Bigas MA, Wolff RA, Das P, et al. Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2006;66:762-71.

15. Desai SP, El-Rayes BF, Ben-Josef E, Greenson JK, Knol JA, Huang EH, et al. A phase II study of preoperative capecitabine and radiation therapy in patients with rectal cancer. Am J Clin Oncol 2007;30:340-5.

16. Hofheinz RD, Wenz F, Post S, Matzdorff A, Lœchelt S, Hartmann JT, et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: A randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol 2012;13:579-88.

17. Kim JS, Cho MJ, Yoon WH, Song KS. Comparison of the efficacy of oral capecitabine versus bolus 5-FU in preoperative radiotherapy of locally advanced rectal cancer. J Korean Med Sci 2006;21:52-7.

18. Yerushalmi R, Idelevich E, Dror Y, Stemmer SM, Figer A, Sulkes A, et al. Preoperative chemoradiation in rectal cancer: Retrospective comparison between capecitabine and continuous infusion of 5-fluorouracil. J Surg Oncol 2006;93:329-33.

19. Chan AK, Wong AO, Jenken DA. Preoperative capecitabine and pelvic radiation in locally advanced rectal cancer—is it equivalent to 5-FU infusion plus leucovorin and radiotherapy? Int J Radiat Oncol Biol Phys 2010;76:1413-9.

20. Ausili Cefaro G, Genovesi D, Vinciguerra A, Augurio A, Di Tommaso M, Marchese R, et al. Effects of preoperative radiochemotherapy with capecitabine for resectable locally advanced rectal cancer in elderly patients. Tumori 2012;98:622-9.

21. Kim DY, Jung KH, Kim TH, Kim DW, Chang HJ, Jeong JY, et al. Comparison of 5-fluorouracil/leucovorin and capecitabine in preoperative
chemoradiotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2007;67:378-84.

22. Roh M, Yothers G, O’Connell M, Beart R, Pitot H, Shield SA, et al. The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04. J Clin Oncol 2011;29:3503.

23. Lee SU, Kim DY, Kim SY, Baek JY, Chang HJ, Kim MJ, et al. Comparison of two preoperative chemoradiotherapy regimens for locally advanced rectal cancer: Capecitabine alone versus capecitabine plus irinotecan. Radiat Oncol 2013;8:258.

24. Chiara S, Nobile MT, Barzacchi C, Sanguineti O, Vincenti M, Di Somma C, et al. Hand-foot syndrome induced by high-dose, short-term, continuous 5-fluorouracil infusion. Eur J Cancer 1997;33:967-9.

**Source of Support:** Nil, **Conflict of Interest:** None declared.